In line with its aim of developing a global vaccines franchise, Astellas Pharma has established a second alliance with Immunomic Therapeutics, this time gaining exclusive access to the company’s LAMP-vax™ (lysosomal-associated membrane protein vaccine) technology platform in the field of human allergic diseases in return for US$300 M upfront plus a 10% royalty rate. The deal comes only months after Astellas licensed rights to a Japanese red cedar pollen vaccine from Immunomic and will allow the US-based company to focus on other therapeutic applications of its platform, including cancer immunotherapy.